0
Original Research: Signs and Symptoms of Chest Diseases |

Validation of the Cough Quality-of-Life Questionnaire in Patients With Idiopathic Pulmonary FibrosisValidation of Cough Quality of Life Questionnaire

Noah Lechtzin, MD, MHS, FCCP; Marisa E. Hilliard, PhD; Maureen R. Horton, MD
Author and Funding Information

From the Johns Hopkins University School of Medicine, Baltimore, MD.

Correspondence to: Noah Lechtzin, MD, MHS, FCCP, Johns Hopkins University School of Medicine, 1830 E Monument St, 5th Floor, Baltimore, MD 21205; e-mail: nlechtz@jhmi.edu


Funding/Support: The Celgene Corporation provided support for the initial clinical trial from which these data were obtained.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2013;143(6):1745-1749. doi:10.1378/chest.12-2870
Text Size: A A A
Published online

Background:  Cough is a pervasive and disabling symptom of idiopathic pulmonary fibrosis (IPF) and is an independent predictor of disease progression. The Cough Quality-of-Life Questionnaire (CQLQ) is a validated measure of cough-specific quality of life that could be used as an outcome measure in therapeutic trials for IPF. This study aimed to assess the reliability and validity of the CQLQ in individuals with IPF.

Methods:  The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF. Participants were adults with IPF and chronic cough. A cough visual analog scale (VAS) and the St. George’s Respiratory Questionnaire (SGRQ) were administered to establish concurrent validity of the CQLQ.

Results:  Internal consistency was high (Cronbach α > .70) for the CQLQ total and four of six subscale scores. The CQLQ total score demonstrated concurrent validity through significant correlations with scores on the cough VAS and SGRQ total and subscale scores (r range, 0.63-0.81; P < .05). The intraclass correlation coefficient for the CQLQ completed at baseline and after a therapeutic washout period at week 15 was 0.87, indicating very good test-retest reliability.

Conclusions:  This study supports the use of the CQLQ as a valid and reliable instrument in IPF and should be used to assess cough-specific quality of life in therapeutic trials.


Sign In to Access Full Content

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.
Want to access your Institution's subscription?
Sign in to your individual user account while you are actively authenticated on this website via your institution (Learn more about institutional authentication). We will then sustain your personal access to their content/subscription for 90 days, after which you can repeat this process.

Sign In to Access Full Content

Want to Purchase a Subscription?

New to CHEST? Become an ACCP member to receive a full subscription to both the print and online editions.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
CHEST Collections
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543